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Abstract
Background: Antisocial personality disorder often co-exists with drug and alcohol use disorders.
Methods: This trial examined the effectiveness of offering psycho-education for antisocial personality disorder in
community substance use disorder treatment centers in Denmark. A total of 176 patients were randomly allocated
to treatment as usual (TAU, n = 80) or TAU plus a psycho-educative program, Impulsive Lifestyle Counselling (ILC, n = 96)
delivered by site clinicians (n = 39). Using follow-up interviews 3 and 9 months after randomization, we examined
changes in drug and alcohol use (Addiction Severity Index Composite Scores), percent days abstinent (PDA) within last
month, and aggression as measured with the Buss-Perry Aggression Questionnaire-Short Form and the Self-Report of
Aggression and Social Behavior Measure.
Results: Overall engagement in psychological interventions was modest: 71 (76 %) of participants randomized to
psycho-education attended at least one counselling session, and 21 (23 %) attended all six sessions. The Median
number of sessions was 2. All patients reduced drug and alcohol problems at 9 months with small within-group effect
sizes. Intention-to-treat analyses indicated significant differences between ILC and TAU in mean drugs composite score
(p = .018) and in PDA (p = .041) at 3 months. Aggression declined in both groups, but no differences between ILC and
TAU were observed in terms of alcohol problems or aggression at any follow-up.
Conclusions: Moderate short-term improvements in substance use were associated with randomization to Impulsive
Lifestyle Counselling. The findings support the usefulness of providing psycho-education to outpatients with antisocial
personality disorder.
Trial registration: ISRCTN registry, ISRCTN67266318, 17/7/2012
Background
Antisocial personality disorder (ASPD) is a serious dis-
turbance that imposes a major burden on individuals
and society [27] and for which there is no effective
treatment [25]. Affected individuals exhibit persistent
antisocial behavior and pervasive antisocial character
traits, such as irritability, manipulativeness, and lack of
remorse [2]. The disorder affects between 1.0 and 3.6 %
of the general population (e.g. [11, 13]), and a substan-
tially greater percentage of patients with substance use
disorders [13]. In terms of developmental psychopath-
ology, there is evidence that ASPD is a lifespan disorder
which originates in childhood [20], and accordingly, the
presence of conduct disorder is a prerequisite to the
adult diagnosis [2].
Treatments for ASPD
Early intervention for children with antisocial behavior
may prevent the development of ASPD and improve
academic performance [46]. As for treatment for adults,
the treatment options that have been tested have been
designed to treat comorbid substance use disorders
(SUDs) or have targeted a specific behavior such as
social problem-solving skills. Overall, evidence for the
efficacy of psychosocial interventions is weak [25]. In
terms of mental health service use, individuals with
ASPD have a high risk of needing emergency psychiatric
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services and inpatient hospitalization [15]. Although
they are not likely to seek treatment for their behavioral
problems, many patients with ASPD do seek treatment
for drug and alcohol problems [24, 50]. Among individ-
uals with SUD, ASPD is a common comorbidity across
classes of substances [26] and is associated with poor
prognosis [14, 33], even years or decades after a diagno-
sis is made ([21–23].
The only published controlled trial of which we are
aware which has tested an intervention directed at any
type of outpatients with ASPD, found a non-significant
trend favoring cognitive behavior therapy over treatment
as usual in terms of alcohol problems, but not in other
outcomes, such as self-reported aggression and social
functioning [16]. However, a potentially important ob-
servation from this controlled trial was that a substantial
proportion of the participants were willing to engage in
treatment and that it is possible to offer treatment to
individuals with ASPD.
Psycho-education
One way to address a personality disorder (PD) is through
psychoeducation. If done sensitively, providing psychoe-
ducation may help raise the patient’s awareness of his
behavioral difficulties and how they impact himself and
others [6]. This awareness may in turn help the patient in
making informed decisions about seeking and receiving
help for problems.
Paradoxically, many clinicians report not providing
psychoeducation to patients with PDs, although they
perceive it to be an important aspect of treatment [44].
Whether or not this applies to other treatment services
and to ASPD is not known, but we are aware of no pub-
lished manuals or studies on how to provide psychoedu-
cation for patients with ASPD.
At present, there is no evidence on psychoeducation
for ASPD, and little on psycho-education with patients
with PD in general. A study of patients with borderline
personality disorder (BPD) found that psychoeducation
had an effect on impulsivity and chaotic interpersonal
relationships, but not on global functioning [56].
While BPD and ASPD are two distinct disorders, they
share central features such as impulsivity and high levels
of anger; therefore it is possible that these findings could
apply to the psychoeducation of patients with ASPD as
well. If patients with ASPD gain a better understanding
of their own personalities, they may identify dysfunc-
tional beliefs and behaviors that emerge in various situa-
tions, such as the belief that it is necessary to dominate
and control others [8, 38], and make informed decisions
about how to change their behavior. Another study of
psychoeducation with patients with PDs was conducted
in two settings - community and forensic. The study did
not have a control group, but after the course of
psychoeducation, patients reported that therapeutic alli-
ance improved [6].
Given that ASPD is highly prevalent among people
with SUD, one context for reaching patients with ASPD
is at substance use treatment services. Some studies have
indicated that treatments that integrate PD as 2an
important component in SUD treatment may reduce
substance abuse among patients with comorbid SUD
and PD when compared to substance abuse treatment
alone, although the integration appears to have little
effect on symptoms and functioning [3–5, 40]. Providing
treatment to people with comorbid ASPD and SUD may
be a challenge; in general, there is a risk of low attend-
ance to psychotherapeutic treatments and counselling at
community-based treatment of substance use disorders
[17, 43], and this risk is exacerbated in patients with
ASPD (e.g. [48]). In conclusion, there is a need for
further development of clinical strategies that can
address the types of problems associated with ASPD in
settings where ASPD is common, such as substance
abuse treatment centers.
Aims
The purpose of this study was to test the efficacy of a brief
psycho-educational intervention, the Impulsive Lifestyle
Counselling program (ILC), as a supplement to standard
substance abuse treatment in a regular outpatient context.
The trial was pragmatic in the sense that the aim was to
test the usefulness of implementing a brief intervention
with limited demands on costs and clinician qualifications
in a standard setting, community substance abuse treat-




The study was a Phase I pragmatic randomized con-
trolled trial with single blind assessments, and was car-
ried out at community-based substance abuse treatment
clinics in 13 municipalities in Denmark between January
2012 and July 2014. Inclusion criteria were: between 18
and 65 years old; met criteria for ASPD using the Mini
International Neuropsychiatric Interview [47], able to
provide written informed consent, and seeking treatment
or already in treatment for a substance use disorder.
Exclusion criteria were: plans that would interfere with
participation in the psychoeducation in the next three
months, such as plans to move away from the uptake
area or waiting to serve a prison sentence, plans to enter
residential rehabilitation or hospitalization, and waiting
to serve a prison sentence. Additionally, patients were
excluded if they were participating in group counselling
or therapy with another patient participating in the trial,
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were known to suffer from an acute psychosis or severe
brain damage, or did not speak Danish.
Ethics
The present project was reviewed by the regional ethics
committee of the Capital Region of Denmark and deemed
exempt from a formal evaluation (J#H-3-2012-FSP45).
This study was done in accordance with the declaration of
Helsinki 2004, which states that it is the duty of the
researcher to protect the life, health, dignity, integrity,
right to self-determination, privacy and confidentiality of
personal information of research subjects (WMA, 2013).
All patients signed separate consent forms to participate
in the study and to be followed up. The Danish Data
Protection Agency evaluated data security for the project
and approved the procedures for data handling and stor-
age. The trial was registered in the ISRCTN register
(#ISRCTN67266318).
Recruitment and randomization
Study participants were identified by clinicians at the par-
ticipating sites from new and existing patients receiving
outpatient treatment for a drug or alcohol problem. After
agreeing to be contacted, relevant participants were
invited by a trained clinician at the site to take part in an
interview to assess the diagnosis of ASPD and the other
inclusion criteria. Those participants who met the inclu-
sion criteria were told that their responses indicated
ASPD, and the counsellor would then review their
responses to the MINI module and ask if they felt that the
behavior described in the response constituted a problem
to them, and if they were willing to speak about it with to
a counsellor. Those who agreed to speak with a counsellor
and provided written informed consent to take part in the
study, subsequently completed the baseline assessment
and were randomly allocated to either one of two active
treatment groups: treatment as usual (TAU) or the Impul-
sive Lifestyle Counselling (ILC). Patients who consented
to participate in the study were also asked to provide
information for follow-up, including telephone numbers,
home address, the addresses and telephone numbers of
family members or others who could help locate the
patient for the follow-up. Patients were also asked to
specify which of a number of alternative contact
sources other than the treatment clinic (prison services,
social services, hospitals, homeless services) that they
would consent to being used to locate them .
Randomization was stratified by clinic. The randomization
schedules were generated by the trial coordinator and kept
secure and confidential at the study coordinating center in
Copenhagen. The randomization schedule was constructed
using the method of randomized permuted blocks of ran-
domly varying size with a ratio of 1:1 (4 or 6 per block).
The trial coordinator informed the referring clinician
of the result of randomization immediately after being
notified that the patient had been assessed and was
found to be eligible for study participation. After this,
the clinician informed the patient of the result. In the
cases in which patients were randomized to the ILC
treatment, the clinician then contacted one of the ILC
counsellors at the uptake unit with the participants’
details so that the sessions could be initiated as quickly
as possible.
Because the randomization had to take place immedi-
ately after the assessment interview, the trial coordinator
was unable to check whether the baseline assessment
was complete before randomizing, and patients with




All participants received whichever form of treatment
they would have received at the participating treatment
service if the trial had not taken place. Treatment al-
ways included: access to opioid substitution treatment
(either methadone, buprenorphine or a combination of
methadone and injectable diacetylmorphine) for pa-
tients who needed it, and psychosocial support in the
form of casework, counselling, or referral to residential
rehabilitation. At some clinics, a liaison psychiatrist
would see the patients on-site, and at other clinics pa-
tients would be referred to an off-site psychiatrist for
diagnosis and treatment of other psychiatric conditions,
such as attention-deficit/hyperactivity disorder, anxiety
or depression.
ILC
In addition to all of the services available to patients who
received TAU, patients randomized to ILC were offered
up to six ILC sessions by a specially trained counsellor.
The ILC program is a highly structured, manual guided
psychoeducational intervention for people with ASPD
[49]. Each session covers a specific topic and includes
questions that the patient must be asked. The form and
content of the sessions were adapted from the manual for
the Lifestyle Issues program [53]. In line with the Lifestyle
Issues program, the key is to support the patient in aware-
ness raising, in recognizing the opportunity to change life-
style and in taking responsibility for addressing behavioral
problems. Similar to the approach by Banerjee and col-
leagues, the psychoeducational intervention is intended to
function as a an educative and collaborative exercise that
can improve further treatment engagement [6].
Each session covers a specific topic and includes ques-
tions that the patient must be asked, and pre-printed
handouts and worksheets are given to the patient. The
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initial session focuses on the purpose of the ILC program
and on identifying thoughts and behavior related to ASPD.
The second session is based on an adapted version of the
Antecedents-Beliefs-Consequences model from Rational-
Emotive Behavior Therapy (Ellis & Dryden, 1997), linking
the patients’ impulsive behaviors to the immediate conse-
quences. Session 3 deals with impulsive and destructive
behavior and how it may be related to specific value
systems and beliefs associated with ASPD. Session 4 pre-
sents the concept of values and discusses which values
may support or prevent the patient in change of lifestyle,
and session 5 focus on the patient’s social networks and
how certain people or groups may support or challenge
lifestyle changes. The last session is a booster session in
which the patient is invited to talk about the topics that he
or she finds most relevant for future efforts to change
behavior.
Like the Lifestyles Issues program, the ILC program
is designed so that no prior training or special facilities
of any sort are necessary. However, prior to delivering
the intervention, all of the counsellors participated in
two-day workshops to practice the strategies described
in the manual and discuss issues related to treating people
with ASPD in general. All counsellors were required to
keep written records and make audio-recordings of the
sessions.
Counsellors in the ILC group did not receive any spe-
cial supervision beyond the supervision that was already
available to staff in their respective clinics, but they did
have the opportunity to call the study organizers with
specific questions concerning the intervention.
Follow-up procedures
For the two follow-up waves, patients were initially con-
tacted through the phone number they had provided. If
it was not possible to establish contact with the person,
the next attempt was to contact the patient through the
clinic at which they had been screened for the study. If a
patient still could not be reached, we asked his or her
case manager at the clinic if there was a time when the
patient was expected to be at the clinic (e.g., times when
the patient would pick up medications). Patients who
could still not be reached were contacted through the
telephone numbers and addresses they had provided,
and finally through other available sources that the pa-
tient had given consent to at the study intake. In a few
cases, the patients were finally located through the Cen-
tral Personal Register. Once a patient had been located,
and if it was possible to speak with the patient directly, a
place and time for an interview was scheduled. If the
patient did not show up for a face-to-face interview, a
new time would be scheduled, and only after several
failed attempts was a telephone interview suggested. If
the patients stated that they were not willing to be
interviewed, they would be asked if they would agree to
be contacted at a later point, and if they refused, they
were not contacted again.
Measures
The Mini International Neuropsychiatric Interview
[MINI] ASPD module was used to assess ASPD [31, 47].
The MINI is a fully structured, brief and valid diagnostic
interview that was designed to assess DSM-IV and ICD-
10 diagnoses [31, 47], which can be conducted by a lay
person and is well accepted by patients [41]. The ASPD
module consists of six questions concerning conduct
disorder and six questions about adult antisocial behav-
ior. Previous research indicates that the MINI module
for ASPD identifies prison inmates with more serious
mental health problems, more substance abuse prob-
lems, a more serious and chronic history of offending
behavior compared with other inmates [9, 32, 35], and is
associated with illicit drug use in the general population
[37]. For the present study, we used the official Danish
translation of the MINI 5.0.0 by P. Besh, G. Bech-
Andersen, and T. Schütze. Also, after each adult anti-
social item on the MINI schedule, staff members asked
about whether the behavior had occurred in the past
year, in order to confirm that the behavior was ongoing.
The sample internal consistency of the lifetime adult
antisocial behavior items was Cronbach’s α = 0.74 at
baseline and α = 0.65 for the conduct disorder criteria.
Additional demographic data were collected on a separ-
ate sheet, including education, employment history, history
of homelessness, residential treatment for substance use
disorder, incarceration, and psychiatric hospitalizations.
Current substance use severity was measured using
the alcohol and drug use composite score from the
Addiction Severity Index (ASI) which have demonstrated
high concordance with DSM-IV substance use disorders
[42], and days abstinent in the previous 30-day period.
All substance use data were collected at baseline and at
each follow-up wave.
Internal consistency for the drugs composite score in this
sample was α = 0.60 at baseline, α = 0.60 at the 3-month
follow-up, and α = 0.64 at the 9-month follow-up. Sample
internal consistency for the alcohol composite score items
was α = 0.89 at baseline, α = 0.92 at the 3 month follow-up,
and α = 0.77 at the 9-month follow-up.
General aggression was measured using the 12-item
version of the Buss-Perry Aggression Questionnaire
(BPAQ, [18]), a commonly used measure of general
aggression in both general population and forensic sam-
ples with good psychometric properties. Sample items
include “Given enough provocation, I may hit another
person.” And “I often find myself disagreeing with
people.” The items are scored on a five-point Likert scale
ranging from 1 (“extremely uncharacteristic of me”) to 5
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(“extremely characteristic of me).” Sample internal
consistency for the BPAQ was α = 0.82 at baseline, α =
0.81 at 3-month follow-up and α = 0.80 at 9-month
follow-up.
Interpersonal aggression was measured using the 14-
item version of the Self-Report of Aggression and Social
Behavior Measure [36], a measure of interpersonal
aggressive acts and dispositions. Sample items include
“My friends know that I will think less of them if they
do not do what I want them to do.” And “When I am
mad at a person, I try to make sure she/he is excluded
from group activities (such as going to the movies or to
a bar).” Items are rated on a five-point Likert scale from
0 (“Never”) to 4 (“Very often”). The internal consistency
for the SRASBM in this sample was α = 0.78 at baseline,
α = 0.81 at the 3-month follow-up, and α = 0.82 at the 9-
month follow-up.
Blinding
Research technicians not affiliated with the clinics car-
ried out all assessments at the 3 and 9-month follow-up
interviews and were blind to treatment group allocation.
ILC adherence rating
Two independent raters evaluated a sample of the audio-
taped ILC sessions for manual adherence. Adherence was
rated on a Likert scale from 1 to 5, in which 1 indicates
low adherence (that the session is largely independent of
the manual), and 5 indicates high adherence (that the
counsellor follows the manual closely).
Calculation of sample size
Assuming equal numbers of participants in intervention
and control arms, a correlation of 0.60 between the same
measure collected at two different points in time, and
two follow-up waves, a total sample size of 146 was cal-
culated for an effect size of 0.40, an alpha level of 0.05,
and a power of 0.80 [19]. To adjust for potential attrition
at follow-up, we aimed to include 200 patients in the
study.
Data analysis
The two groups were compared in terms of baseline
characteristics using χ2 tests for dichotomous variables,
and t-tests for continuous variables.
We report means and standard deviations for
dependent variables at baseline, the 3 and 9-month
follow-ups, and standard mean differences [SMD]
between baseline and each follow-up wave within both
groups. The SMD was calculated as the difference
between baseline and follow-up mean, divided by the
baseline standard deviation for the group. It is common
to describe an SMD of 0.2 as small, 0.5 as medium, and
0.8 as a large effect size, following Cohen [10]. Fixed-
effects regression analysis was used to assess the statis-
tical significance of within-group changes.
Random-effects regression was used to assess the
effects on substance use and aggression at the 3 and 9-
month follow-up points after randomization. The out-
come analyses were by intent-to-treat, i.e. analyzed by
randomization arm irrespective of attendance or treat-
ment compliance. Random effects were estimated for
both patient and site, and covariates were gender, age,
and receiving substitution treatment at baseline. The
predictors were randomization status and assessment
wave, and the interaction of randomization status and
assessment wave. All analyses were controlled for opioid
substitution treatment because such medication may
substantially influence both illicit drug use and use of
treatment services, adding significant variance to the
dependent variables in ways that could potentially mask
effects of treatment.
Patients were included in the outcome analyses if they
had complete data at baseline and at least one follow-up.
For days abstinent, we also report the proportion at each
follow-up wave who reported no days of substance use
(i.e., current abstinence) and the proportion who reported
use all days (i.e., 30 days of use in the past 30 days).
Results
The flow of patients through the trial is illustrated in
Fig. 1.
A total of 142 patients had complete data, including at
least one follow-up wave, and could be included in the
analyses, of which 64 were assigned to TAU and 78 to
ILC. The sample was 87 % male, the mean age was
32.21 years of age ([SD] = 8.90), and 36.5 % received opi-
oid substitution treatment at the time of randomization.
The most commonly used drugs in the past 30 days
were cannabis (69.9 %), alcohol (67.1 %), benzodiaze-
pines (41.8 %) and opioids (41.3 %).
Baseline equivalence
We compared the ILC and TAU groups at baseline, re-
gardless of whether they had been re-interviewed or not.
The descriptive statistics are shown in Additional file 1:
Table S1.
There were no significant differences in terms of drugs or
alcohol composite scores, PDA, or aggression scores at
baseline. However, patients in the ILC group reported more
days of amphetamine use than TAU patients (p < 0.05), and
were more often abstinent in the past month at baseline
(χ2(1) = 3.52, p = 0.029).
Exposure to the intervention
Of the 96 patients originally randomized to the ILC
group, 71 (76 %) attended at least one session, and 22
(23 %) attended all six sessions. The median number of
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sessions attended was 2, and the mean was 2.8 (SD = 2.4).
For patients who attended the first session, the median ILC
time before the first session was 26 days (inter-quartile
range: 13 to 59 days). A total of 39 different counsellors
delivered the ILC intervention.
Manual adherence
Of the 80 audiotaped sessions rated, 20.3 % were rated
as a 5 on the adherence scale, 72.2 % were rated as a 4,
and 7.6 % were rated as a 2 or 3.
Follow-up
The follow-up rate at 3 months was 79 % (81 % in the
TAU group and 77 % in the ILC group) and 69 % at
9 months (71 % in the TAU group and 68 % in the ILC
group). Of all follow-up interviews, 75 % were con-
ducted at substance abuse treatment clinics, 9 % in the
interviewees’ homes, 3 % in prisons, 12 % in other
places, 1 % were conducted as telephone interviews, and
12 % were conducted in various other places, including
cafés, and public libraries.
Attrition analyses
We compared patients with at least one follow-up inter-
view with patients who had never been re-interviewed in
terms of age, gender, drugs and alcohol composite score,
adult ASPD criteria, substitution treatment at baseline,
and in terms of intake unit. No differences between
patients interviewed and patients lost to follow-up
attained statistical significance, except that there was a
difference between clinics in terms of follow-up rate
(χ2(12) = 25.7, p = 0.012). Rates of patients interviewed at
least once ranged from 63 % in some clinics to 100 % in
others.
Substance use outcomes
Mean values for substance use variables in both groups
at all assessment waves are summarized in Table 1. Each
row contains the mean and standard deviation at each
assessment wave for each group, as well as the standard
mean difference as an effect size indicating within-group
change. In addition to means and standard deviations
for the dependent variables and standardized mean dif-
ferences, Table 1 shows the percentage of patients with
Fig. 1 Flow diagram
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past-month abstinence (i.e., percent reporting zero days
of use) and the percentage of daily users (percent report-
ing 30 days of use in the past 30 days).
The ILC group had reduced their drug use composite
score by a small effect size at 3 months (SMD= 0.23, p =
0.042) and at 9 months (SMD = 0.42, p = 0.000). The
TAU group increased their drug use composite score
by a small effect size at 3 months (SMD = −0.12, ns)
and reduced it by a small effect size at 9 months (SMD=
0.27, p = 0.001).
The ILC group reduced their alcohol use composite
score by a small effect size (SMD = 0.22, ns) at 3 months
and at 9 months (SMD = 0.11, ns). The TAU group
reduced their alcohol use severity with a small effect size
(SMD = 0.14, ns) at 3 months and at 9 months (SMD =
0.22. p = 0.020).
The ILC group increased their days abstinent with a
small effect size at 3 months (SMD = 0.38, p = 0.042) and
a moderate effect size at 9 months (SMD = 0.58, p <
0.001). The TAU group reduced their days abstinent by a
small effect size at 3 months (-0.09, ns) and increased it
by a small effect size by at 9 months (0.17, ns).
The proportion of patients who reported being com-
pletely abstinent was stable in the TAU group, at 12 % at
baseline, and 13 % at 3 months follow-up and at 9 months
follow-up. In the ILC group, 3 % were abstinent at base-
line, 17 % at 3 months and 21 % at 9 months. As for daily
use, the TAU group reported 36 % at baseline and 36 %
and 33 % at the two follow waves. In the ILC group 42 %
reported daily use at baseline and 37 and 31 % did so at
the follow up waves.
The results of mixed effects regression on substance
use outcomes are summarized in Table 2. For each
dependent variable, Table 2 reports the effects of
assessment wave for 3 and 9 months follow-up, and the
interaction between randomization and assessment
wave for both waves. Additionally, the table contains
the intraclass correlations for randomization site and
patient with 95 % confidence intervals, and the model
Wald χ2. For the ASI drugs composite score, the Wald
χ2 was 93.90 (df = 8, p < 0.001). Patients randomized to
the ILC group had significantly less drug use at the 3-
month follow-up compared to the TAU group (β =−0.041,
p = 0.018). In addition to the ILC and time variables,
patients who received opioid substitution treatment at
baseline had more severe drug use (β = 0.11, p < 0.001).
For the alcohol composite score, the Wald χ2 was
16.24 (df = 8, p = 0.039), and there was no significant
effect of randomization at either follow-up wave. The
whole group decreased their level of alcohol problems at
9 months (p = 0.011).
For days abstinent, the Wald χ2 was 31.17, (df = 8, p <
0.001), and patients randomized to the ILC group reported
4.3 more days abstinent at 3 month follow-up (CI: 0.18 to
8.46). Additionally, patients who received substitution
treatment had fewer days abstinent (β = −5.64, p = 0.003).
Aggression outcomes
Mean values for aggression variables in both groups at
all assessment waves are summarized in Table 3. Table 3
is presented similarly to Table 1.
The ILC group reduced their general aggression (BPAQ)
with a moderate effect size at 3 months (SMD= 0.51, p <
0.001) and a large effect size at 9 months (SMD= 0.76, p <
0.001). The TAU group reduced their general aggression
with a moderate effect size at 3 months (SMD= 0.50, p <
0.001) and increased it by a large effect size by at 9 months
(0.76, p < 0.001).
The ILC group reduced their interpersonal aggression
(SRASBM) with a small effect size at 3 months (SMD =
0.57, p < 0.001), and at 9 months (SMD= 0.72, p < 0.01).
The TAU group reduced their interpersonal aggression
with a moderate effect size at 3 months (SMD= 0.57, p <
0.001) and a moderate effect size at 9 months (SMD=
0.61, p < 0.001).
The results of mixed effects regression on outcomes
are summarized in Table 4. Similar to Table 2, for each
dependent variable, Table 4 reports the effects of assess-
ment wave for 3 and 9 months follow-up, and the inter-
action between randomization and assessment wave for
both waves, the intraclass correlations for randomization
site and patient with 95 % confidence intervals, and the















ASI drugs CS 0.19 (0.13) 0.21 (0.12) −0.12 0.16 (0.13) 0.27** 0.20 (0.13) 0.17 (0.12) 0.23* 0.15 (0.12) 0.42**
ASI alcohol CS 0.15 (0.22) 0.12 (0.22) 0.14 0.10 (0.18) 0.22* 0.14 (0.22) 0.12 (0.22) 0.22 0.12 (0.21) 0.10
Days Abstinent 11.8 (11.7) 10.8 (11.2) −0.09 13.7 (12.7) 0.17 9.07 (10.9) 13.2 (12.7) 0.38* 15.3 (13.3) 0.58**
Abstinent 12 % 13 % 13 % 3 % 17 % 21 %
Daily use 36 % 36 % 33 % 42 % 37 % 31 %
Abstinent indicates zero days of illicit drug or alcohol use out of the past 30. Significant differences in fixed-effects regression: *: p < 0.05. **p < 0.01. Nine participants
had not completed data on substance use at baseline
TAU Treatment as usual, ILC Impulsive lifestyle counselling, ASI Addiction Severity Index, CS Composite score, SMD standard mean difference
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model Wald χ2. For the BPAQ, the Wald χ2 was 101.82
(df = 8, p < 0.001). No differences were found between
ILC and TAU at any point, but across both groups, con-
siderable reductions in general aggression were observed
at both follow-up waves.
For the SRASBM, the Wald χ2 was 124.43 (df = 8, p <
0.001), and there was no significant effect of randomization
at either follow-up wave. No differences were found
between ILC and TAU at any point, but across both groups
considerable reductions in interpersonal aggression were
observed at both follow-up waves.
Discussion
This trial provides the first evidence that the ILC pro-
gram, a short-term, highly structured psychoeducational
intervention, increases the efficacy of treatment for sub-
stance use disorders for patients with comorbid ASPD
and substance use disorder.
At the 3-month follow-up, patients who had been ran-
domized to the ILC group had increased days abstinent
compared to patients randomized to TAU and had less
severe drug use. As is typical in community substance
abuse treatment contexts, attendance to the intervention
Table 2 Results of mixed effects regression on substance use outcomes (n = 142)
Dependent variable Coefficient 95 % CI P-value
ASI Drugs CS ILC intercept 0.001 −0.026 to 0.046 0.588
3 months 0.015 −0.017 to 0.047 0.362
9 months −0.052 −0.086 to−0.019 0.002
ILC X 3 months −0.052 −0.096 to−0.009 0.018
ILC X 9 months −0.004 −0.049 to 0.042 0.872
ICC site 0.017 0.000 to 0.361
ICC Patient 0.335 0.234 to 0.455
Wald χ2(8) 93.90 0.000
ASI Alcohol CS ILC intercept −0.012 −0.077 to 0.052 0.708
3 months −0.041 −0.092 to 0.010 0.134
9 months −0.066 −0.120 to−0.112 0.016
ILC X 3 months 0.008 −0.061 to 0.077 0.814
ILC X 9 months 0.049 −0.023 to 0.121 0.182
ICC Site 0.072 0.016 to 0.272
ICC Patient 0.506 0.402 to 0.610
Wald χ2(8) 16.24 0.039
Days abstinent ILC intercept −2.300 −6.179 to 1.580 0.245
3 months 0.970 −4.027 to 2.088 0.534
9 months 2.359 −0.863 to 5.810 0.151
ILC X 3 months 4.319 0.183 to 8.456 0.041
ILC X 9 months 3.584 −0.751 to 7.919 0.105
ICC Site 0.005 0.000 to 1.000
ICC Patient 0.471 0.369 to 0.576
Wald χ2(8) 31.17 0.000
All analyses adjusted for site and individual, gender, age, and substitution at baseline
TAU Treatment as usual, ILC Impulsive lifestyle counselling, ASI Addiction Severity Index, CS Composite score, ICC Intraclass correlation















BPAQ 4.44 (1.20) 3.83 (1.16) 0.50** 3.52 (1.25) 0.76** 4.38 (1.10) 4.01 (1.16) 0.34** 3.59 (1.05) 0.72**
SRASBM 1.00 (0.63) 0.64 (0.46) 0.57** 0.61 (0.52) 0.61** 0.93 (0.61) 0.64 (0.49) 0.47** 0.47 (0.39) 0.75**
Nine participants had not completed data on aggression at baseline
TAU Treatment as usual, ILC Impulsive lifestyle counselling, BPAQ Buss-Perry Aggression Questionnaire, SRASBM Self-Report of Aggression and Social Behavior
Measure, SMD standard mean difference ** p < 0.01
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was less than perfect. In spite of this, the intention-to-
treat analysis supported the benefits of the treatment.
No statistically significant effects were observed for
self-reported aggression. Across both groups, substantial
decreases in self-reported aggression were observed at
both follow-up waves, indicating either that participation
in substance abuse treatment reduced aggression, or
alternatively a regression to the mean effect [7], or a
retest artefact [45]. It is plausible that the intervention
was too brief to have an impact on aggressive behavior.
However, the findings are similar to those of a somewhat
more intensive intervention with cognitive behavioral
therapy for psychiatric outpatients with ASPD, where
some effect on substance use was observed, but none on
self-reported aggression [16].
The brief non-intensive intervention delivered in this
study is not a cure for ASPD, but can constitute one of
many small steps towards improving treatment for this
under-served population. Substance use is a factor that
complicates the treatment of any psychiatric disorder, and
if substance use is reduced, it opens up the possibility of
further interventions and support, potentially increasing
the patient’s social and psychological stability.
As in several previous studies, we found evidence that
individuals with ASPD reduced substance use during
standard substance abuse treatment [1, 39]; in the entire
sample, alcohol and drugs composite scores were signifi-
cantly reduced at the 9-month follow-up. These findings
add further support to the view that individuals with
ASPD should not be excluded from substance abuse
treatment [28, 34, 39]. On the other hand, reductions in
substance use generally represented small effect sizes.
Considering the results in Table 1, differences between
the two groups were more pronounced in terms of
patients remaining completely abstinent, than in terms
of patients using non-prescription drugs or alcohol daily;
in both the ILC and the TAU condition, the proportion
of patients using substances daily was stable over time,
whereas the proportion of patients that were abstinent
increased in the ILC group.
The ILC program did not have a significant impact on
the alcohol composite score. In fact, the control group
had reduced their level of alcohol severity by a small
effect size at 9 months, whereas the ILC group was vir-
tually unchanged. However, given that it did not attain
statistical significance, speculating about the reasons for
this negative finding is unwarranted.
The current trial supported the findings by Davidson
and colleagues that substance use could be influenced by
targeting ASPD using a psychosocial intervention [16].
An additional finding from this study was that the
group of patients who received opioid substitution medi-
cation at baseline had more severe drug problems and
fewer days abstinent over the course of the trial. This
finding does not necessarily indicate that substitution
treatment is ineffective, as it may just as well reflect pre-
existing higher severity of drug problems in the opioid
substitution group.
Limitations and strengths
Several limitations for this study must be acknowledged.
First, we had only self-reported data on substance use
with no biological verification available. It is no longer
standard to use biological data for collecting data on
Table 4 Results of mixed effects regression on aggression outcomes (n = 142)
Dependent variable Coefficient 95 % CI P-value
Buss-Perry Aggression Questionnaire ILC intercept −0.121 −0.500 to 0.258 0.533
3 months −0.693 −0.946 to−0.440 0.000
9 months −0.967 −1.234 to−0.700 0.000
ILC X 3 months 0.334 −0.001 to 0.677 0.056
ILC X 9 months 0.199 −0.161 to 0.558 0.279
ICC site 0.000 0.000 to 0.000
ICC Patient 0.620 0.532 to 0.702
Wald χ2(8) 99.24 0.000
SRASBM ILC intercept −0.084 −0.256 to 0.088 0.339
3 months −0.392 −0.522 to−0.261 0.000
9 months −0.460 −0.597 to−0.322 0.000
ILC X 3 months 0.083 −0.092 to 0.260 0.351
ILC X 9 months 0.026 −0.158 to 0.210 0.782
ICC Site 0.000 0.000 to 0.000
ICC Patient 0.513 0.413 to 0.612
Wald χ2(8) 116.95 0.000
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drug use (e.g. [17, 30]), and a number of studies have
indicated that biological verification underestimates sub-
stance use and does not provide more valid data than
self-reporting (e.g. [12, 51, 52]). Another limitation is
that the patient population in this study was heteroge-
neous, including patients using a wide range of sub-
stances, and with a wide age range. On the other hand,
this means that most patients in substance abuse treat-
ment with ASPD would meet inclusion criteria and
could thus/potentially increase the generalizability of the
findings [29, 57].
A further limitation is that we were not able to imple-
ment a standard of treatment as usual. The participating
clinics represented a wide range of rural and urban
settings, and the service level depended on the local
authorities and the division of labor between local psy-
chiatric, social, and substance abuse treatment services,
making it infeasible to standardize the treatment. Since
the intention of ILC is to increase help-seeking behavior
and compliance with treatment, it did not seem pertinent
to control for overall amount of services received.
Further, the absence of an attention placebo condition
meant that the efficacy of the study may be overesti-
mated in the present analyses.
The principle strength of this study lies mainly in its
pragmatic approach to implementing screening and
intervention in a way that is practically feasible at
busy clinics [17]. The intervention was specifically se-
lected to require minimal training of clinicians, yet
had a notable impact on the reduction of substance
use.
Although this study adds to the development of
evidence-based targeted interventions for personality
disorders and ASPD, further research is needed to assess
the relative usefulness and credibility of psychoeducative
programs such as Impulsive Lifestyle Counselling or the
models used by Banerjee et al. [6] or Zanarini and Fran-
kenburg [56] for patients with ASPD.
Of particular interest would be studies with a focus
on ASPD that examine different approaches at
substance abuse treatment services and compare them
to other services offered to patients with ASPD in
terms of their efficacy, their costs and the ease of
implementation.
Conclusion
Impulsive lifestyle counselling, a brief psychoeducative
intervention, had an impact on substance use in terms
of drug use problems and days abstinent for outpatients
with substance use disorders and antisocial personality
disorder. More research is needed on how to provide
optimal treatment for people with antisocial personality
disorder.
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